Abstract
Anti-rabies vaccines (ARVs) with good immunogenic capacity play an important role in controlling the deadly zoonotic rabies in Sri Lanka. The ARVs currently marketed in the country have not been tested for their efficacy and potency at the local level before being released to the market. This article outlines the proposed project formulated to determine the efficacy and potency of these ARVs in generating immunity against rabies. The authors propose that this project will be articulated in three main categories. Part I will be the immunogenicity measurement using, New Zealand White rabbits as the animal model. Part II will be a field study with a sample dog population, including domestic and free-roaming dogs and Part III will be the potency testing of the ARVs using the mouse challenge test. Immunogenicity will be assessed by measuring the humoral immunity development following vaccination, using the methods of Florescent Antibody Virus Neutralization (FAVN) and ELISA. The project will be conducted in collaboration with WHO/WOAH Reference Laboratory for Rabies in Nancy, France, and Medical Research Institute, Colombo 08, Sri Lanka.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
